Osimertinib (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Osimertinib" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

8nih.gov

4^th place

8^th place

5doi.org

2^nd place

5^th place

2web.archive.org

1^st place

2^nd place

2fda.gov

447^th place

409^th place

1europa.eu

68^th place

28^th place

1who.int

195^th place

64^th place

1cam.ac.uk

670^th place

1,054^th place

1medicines.org.uk

3,823^rd place

3,244^th place

cam.ac.uk

repository.cam.ac.uk

Tan CS, Gilligan D, Pacey S (september 2015). »Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer«. The Lancet. Oncology. 16 (9): e447–e459. doi:10.1016/S1470-2045(15)00246-6. PMID 26370354.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

doi.org

Ayeni D, Politi K, Goldberg SB (september 2015). »Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer«. Clinical Cancer Research. 21 (17): 3818–3820. doi:10.1158/1078-0432.CCR-15-1211. PMC 4720502. PMID 26169963.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Tan CS, Gilligan D, Pacey S (september 2015). »Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer«. The Lancet. Oncology. 16 (9): e447–e459. doi:10.1016/S1470-2045(15)00246-6. PMID 26370354.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Xu M, Xie Y, Ni S, Liu H (Maj 2015). »The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)«. Annals of Translational Medicine. 3 (7): 96. doi:10.3978/j.issn.2305-5839.2015.03.60. PMC 4430733. PMID 26015938.
Patel H, Pawara R, Ansari A, Surana S (december 2017). »Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance«. European Journal of Medicinal Chemistry. 142: 32–47. doi:10.1016/j.ejmech.2017.05.027. PMID 28526474.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Wang S, Song Y, Liu D (Januar 2017). »EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance«. Cancer Letters. 385: 51–54. doi:10.1016/j.canlet.2016.11.008. PMID 27840244.

europa.eu

ema.europa.eu

»Tagrisso EPAR«. Evropska agencija za zdravila (EMA). Pridobljeno 16. oktobra 2020.

fda.gov

»FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer«. U.S. Food and Drug Administration (FDA) (tiskovna objava). 18. december 2020. Pridobljeno 20. decembra 2020.

accessdata.fda.gov

»Tagrisso (osimertinib) tablets«. U.S. Food and Drug Administration (FDA). 22. december 2015. Pridobljeno 16. oktobra 2020. Laični povzetek (PDF). {{navedi splet}}: Sklic uporablja opuščeni parameter |lay-url= (pomoč)

medicines.org.uk

»UK label« (v angleščini). UK Electronic Medicines Compendium. 26. januar 2017. Arhivirano iz spletišča dne 27. februarja 2017. Pridobljeno 27. februarja 2017.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ayeni D, Politi K, Goldberg SB (september 2015). »Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer«. Clinical Cancer Research. 21 (17): 3818–3820. doi:10.1158/1078-0432.CCR-15-1211. PMC 4720502. PMID 26169963.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Tan CS, Gilligan D, Pacey S (september 2015). »Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer«. The Lancet. Oncology. 16 (9): e447–e459. doi:10.1016/S1470-2045(15)00246-6. PMID 26370354.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Xu M, Xie Y, Ni S, Liu H (Maj 2015). »The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)«. Annals of Translational Medicine. 3 (7): 96. doi:10.3978/j.issn.2305-5839.2015.03.60. PMC 4430733. PMID 26015938.
Patel H, Pawara R, Ansari A, Surana S (december 2017). »Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance«. European Journal of Medicinal Chemistry. 142: 32–47. doi:10.1016/j.ejmech.2017.05.027. PMID 28526474.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Wang S, Song Y, Liu D (Januar 2017). »EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance«. Cancer Letters. 385: 51–54. doi:10.1016/j.canlet.2016.11.008. PMID 27840244.

ncbi.nlm.nih.gov

Ayeni D, Politi K, Goldberg SB (september 2015). »Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer«. Clinical Cancer Research. 21 (17): 3818–3820. doi:10.1158/1078-0432.CCR-15-1211. PMC 4720502. PMID 26169963.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Xu M, Xie Y, Ni S, Liu H (Maj 2015). »The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)«. Annals of Translational Medicine. 3 (7): 96. doi:10.3978/j.issn.2305-5839.2015.03.60. PMC 4430733. PMID 26015938.

dailymed.nlm.nih.gov

»Tagrisso- osimertinib tablet, film coated«. DailyMed. 5. junij 2020. Pridobljeno 16. oktobra 2020.

web.archive.org

»Proposed INN: List 113« (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Arhivirano (PDF) iz spletišča dne 28. aprila 2017. Pridobljeno 16. novembra 2015.
»UK label« (v angleščini). UK Electronic Medicines Compendium. 26. januar 2017. Arhivirano iz spletišča dne 27. februarja 2017. Pridobljeno 27. februarja 2017.

who.int

»Proposed INN: List 113« (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Arhivirano (PDF) iz spletišča dne 28. aprila 2017. Pridobljeno 16. novembra 2015.